Oral Cabotegravir + Rilpivirine versus Efavirenz + 2 NRTI’s
LATTE Study
Oral Cabotegravir + Rilpivirine versus Efavirenz + 2 NRTI’s
LATTE Study: Design

### Study Design:

- **Background**: Phase 2b, randomized, partially blinded study done at multiple centers in the US and Canada.

- **Inclusion Criteria (n = 244)**
  - Age ≥ 18
  - Antiretroviral-naïve
  - HIV RNA > 1,000 copies/mL
  - CD4 count > 200 cells/mm³
  - CrCl > 50 mL/min
  - No hepatitis B
  - No significant transaminitis

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAB 10 mg + 2 NRTI’s</td>
<td>60</td>
</tr>
<tr>
<td>CAB 30 mg + 2 NRTI’s</td>
<td>60</td>
</tr>
<tr>
<td>CAB 60 mg + 2 NRTI’s</td>
<td>61</td>
</tr>
<tr>
<td>CAB 10 mg + RPV 25 mg</td>
<td>52</td>
</tr>
<tr>
<td>CAB 30 mg + RPV 25 mg</td>
<td>51</td>
</tr>
<tr>
<td>CAB 60 mg + RPV 25 mg</td>
<td>53</td>
</tr>
<tr>
<td>Efavirenz 600 mg + 2 NRTI’s</td>
<td>62</td>
</tr>
<tr>
<td>Efavirenz 600 mg + RPV 25 mg</td>
<td>46</td>
</tr>
</tbody>
</table>

**24-week lead-in phase**

Oral Cabotegravir + Rilpivirine versus Efavirenz + 2 NRTI’s LATTE Study: Results

*Cabotegravir data is composite of all cabotegravir doses

Cabotegravir + 2NRTIs followed by Cabotegravir + RPV

LATTE Trial: Results

*During induction phase cabotegravir administered with investigator chosen 2NRTIs

Interpretation: “Cabotegravir plus dual NRTI therapy had potent antiviral activity during the induction phase. As a two drug maintenance therapy, cabotegravir plus rilpivirine provided antiviral activity similar to efavirenz plus dual NRTIs until the end of week 96. Combined efficacy and safety results lend support to our selection of oral cabotegravir 30 mg once a day for further assessment. LATTE precedes studies of the assessment of longacting injectable formulations of both drugs as a two-drug regimen for the treatment of HIV-1 infection.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

*The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.*